Haemonetics Corporation has completed its acquisition of OpSens, the company announced in a press release today. Haemonetics acquired all outstanding shares of OpSens for CAD2.90pershareintheall−cashtransaction,representingafullydilutedequityvalueofapproximatelyUS2.90 per share in the all-cash transaction, representing a fully diluted equity value of approximately US255 million at the current exchange rate. “Expanding our hospital portfolio with OpSens’ products creates exciting […] The post Haemonetics completes acquisition of OpSens appeared first on Cardiovascular News .